SOUTH SAN FRANCISCO, CA, Human Immunology Biosciences announced its launch with $120 million in financing.
Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. The company was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices.
Human Immunology Biosciences, is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs).
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about